Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis

Virology Journal

Hong Ren¹  Peng Hu¹  Da-Zhi Zhang¹  Huai-Dong Hu¹  Shi-Wen Tong¹  Jun-Ying Liu¹  Yun-Jian Sheng¹ 

[1] Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

关键词: Combination therapy;    Resistance;    Entecavir;    Adefovir;    Lamivudine;    Chronic Hepatitis B;   

Others  :  1156335
DOI  :  10.1186/1743-422X-8-393

 received in 2011-05-16, accepted in 2011-08-08,  发布年份 2011

【 摘 要 】

Background

Chronic hepatitis B virus (HBV) infection represents a serious global health problem and resistance to lamivudine (LAM) has become a serious clinical challenge. Previous rescue therapy for the treatment of chronic LAM-resistant hepatitis B infected patients included switching to entecavir (ETV) and adding adefovir (ADV) or tenofovir (TFV). At present, switching to ETV is not recommended for rescue therapy for LAM-resistant chronic hepatitis B (CHB). The aim of this report was to determine whether add-on ADV was a superior rescue strategy in the treatment of CHB patients with LAM resistance.

Methods

We searched Medline/PubMed, EMBASE, Web of Knowledge, and the Cochrane Library. Relative risks (RRs) of virologic response, virologic breakthrough, normalization of serum alanine aminotransferase (ALT) levels and HBeAg seroconversion rates were studied. Factors predicting virologic response, standardized mean differences (SMD) in HBV DNA levels and safety were reviewed.

Results

Six eligible trials (451 patients in total) were included in the analysis. The rate of virologic breakthrough in the ETV group was higher than that in the LAM plus ADV group. There were no statistical differences in virologic response, ALT normalization and HBeAg seroconversion in either group 48 weeks post treatment. LAM plus ADV combination therapy produced faster and greater HBV DNA reduction rates 24 weeks post therapy compared to ETV monotherapy. HBV DNA baseline levels and the initial virologic response (IVR) were predictive of the virologic response. Additionally, combination therapy or monotherapy were both well tolerated.

Conclusions

LAM plus ADV combination therapy was more effective and produced longer-lasting effects than switching to ETV monotherapy in treating CHB patients with LAM resistance. However, considering the practical benefits and limitations of ADV, individualized therapy will be needed in patients with prior history of LAM resistant infections.

【 授权许可】

   
2011 Sheng et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Cao GW: Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol 2009, 15(46):5761-5769.
• [2]Ganem D, Prince AM: Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med 2004, 350(11):1118-1129.
• [3]Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295(1):65-73.
• [4]Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ: Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130(3):678-686.
• [5]Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, Locarnini S, Martin P, Richman DD, Zoulim F: Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008, 134(2):405-415.
• [6]Zhang QQ, An X, Liu YH, Li SY, Zhong Q, Wang J, Hu HD, Zhang DZ, Ren H, Hu P: Long-Term Nucleos(t)ide Analogues Therapy for Adults With Chronic Hepatitis B reduces the Risk of Long-Term Complications: a meta-analysis. Virol J 2011, 8:72. BioMed Central Full Text
• [7]Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N: Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat 2009, 16(4):265-271.
• [8]Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L: Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003, 36(6):687-696.
• [9]Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2007, 45(2):507-539.
• [10]Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K, Arterburn S, Chuck SL: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006, 131(6):1743-1751.
• [11]Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S, Borroto-Esoda K, Frederick D, Rousseau F: Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008, 48(3):750-758.
• [12]Gaia S, Barbon V, Smedile A, Olivero A, Carenzi S, Lagget M, Alessandria C, Rizzetto M, Marzano A: Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine. J Hepatol 2008, 48(4):540-547.
• [13]Chen EQ, Wang LC, Lei J, Xu L, Tang H: Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. Virol J 2009, 6:163. BioMed Central Full Text
• [14]Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006, 354(10):1011-1020.
• [15]Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, Chao YC, Lee SD, Harris M, Yang J, Colonno R, Brett-Smith H: Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007, 133(5):1437-1444.
• [16]Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, Lesmana L, Yuen MF, Jeffers L, Sherman M, Min A, Mencarini K, Diva U, Cross A, Wilber R, Lopez-Talavera J: Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology 2009, 49(1):72-79.
• [17]Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ: Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009, 49(5):1503-1514.
• [18]Lok AS, McMahon BJ: Chronic hepatitis B: update 2009. Hepatology 2009, 50(3):661-662.
• [19]Pawlotsky JM: EASL Clinical Practice Guidelines. J Hepatol 2009, 50(2):243..
• [20]Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996, 17(1):1-12.
• [21]Chung GE, Kim W, Lee KL, Hwang SY, Lee JH, Kim HY, Jung YJ, Kim D, Jeong JB, Kim BG, Kim YJ, Yoon JH, Lee HS: Add-On Adefovir Is Superior to a Switch to Entecavir as Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B. Dig Dis Sci 2011 Jul, 56(7):2130-2136.
• [22]Ryu HJ, Lee JM, Ahn SH, Kim do Y, Lee MH, Han KH, Chon CY, Park JY: Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. J Med Virol 2010, 82(11):1835-1842.
• [23]Qiu YW, Jiang XH, Huang LH, Hu TH, Ding H, Jiang YM, Dai YX, Zhou M: [A study on the treatment of chronic hepatitis B with YMDD mutation]. Zhonghua Gan Zang Bing Za Zhi 2009, 17(3):171-174.
• [24]Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI: Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. J Gastroenterol Hepatol 2010, 25(8):1374-1380.
• [25]Pellicelli AM, Barbarini G, Romano M, Furlan C, Paffetti A, Villani R, D'Ambrosio C, Guarascio P, Cerasari G, Fondacaro L, Mazzoni E, Barlattani A, Mecenate F, Nosotti L, Puoti C, Morrone A, Gentilucci UV, Picardi A, Lusi AE, Andreoli A, Soccorsi F: Entecavir therapy for Lamivudine resistant HBV cirrhotic patients waiting for olt: Viral and biochemical outcomes at one year. Hepatology 2009, 50(SUPPL.4):514A.
• [26]Lee HW, Kim HJ, Choi CH, Do JH, Chang SK: Entecavir rescue therapy versus adefovir combination therapy in lamivudine-refractory patients with chronic hepatitis B. Hepatology International 2010, 4(1):132-133.
• [27]Yim HJ, Seo YS, Kim JH, Kim CW, Lee CD, Park SH, Lee MS, Park CKN, Chae HB, Kim MY, Baik SK, Kim YS, Kim JH, Il Lee J, Um SH: Adding adefovir compared with switching to entecavir in paients with lamivudine-resistant chonic heaptitis B (ACE STUDY) - a multicenter prospective randomized study: one-year interim analysis. Hepatology 2010, 52(SUPPL.4):560A.
• [28]Jang E, Lee J, Yoon J, Cho E, Yang H, Kwak M, Ahn D, Hwang S, Yu S, Lee C, Kim Y, Lee H: The comparison of three rescue treatment strategies for lamivudine-resistant chronic hepatitis B: lamivudine and adefovir combination therap, entecavir monotherapy, and adefovir monotherapy. Hepatology 2010, 52(SUPPL 4):520A.
• [29]Liaw YF: Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther 2006, 11(6):669-679.
• [30]Ghany MG, Doo EC: Antiviral resistance and hepatitis B therapy. Hepatology 2009, 49(5 Suppl):S174-184.
• [31]Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J, Kreter B, Hindes R: Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008, 48(1):99-108.
• [32]Suzuki F, Toyoda J, Katano Y, Sata M, Moriyama M, Imazeki F, Kage M, Seriu T, Omata M, Kumada H: Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J Gastroenterol Hepatol 2008, 23(9):1320-1326.
• [33]Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P, Ayres A, Bartholomeusz A, Sievert W, Thompson G, Warner N, Locarnini S, Colonno RJ: Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004, 48(9):3498-3507.
• [34]Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trepo C, Zoulim F: Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007, 46(3):531-538.
• [35]Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M: Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007, 133(5):1445-1451.
• [36]Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ: Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007, 45(2):307-313.
• [37]Yatsuji H, Suzuki F, Sezaki H, Akuta N, Suzuki Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Kumada H: Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol 2008, 48(6):923-931.
• [38]Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ: Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol 2010, 53(3):449-454.
• [39]Ryu H, Lee JM, Ahn SH, Kim DY, Lee KS, Han K-H, Chon CY, Moon YM, Park JY: Comparision of entecavir (ETV) monotherapy and lamivudine (LAM) plus adefovir (ADV) in patients with chronic hepatitis B who have sequentially failed with LAM and ADV. Hepatology International 2010., 4(1) 1(165)
• [40]Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trepo C, Zoulim F: Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008, 48(5):747-755.
• [41]Gerolami R, Bourliere M, Colson P, Halfon P, Borentain P, Henry M, Botta D, Thibault V, Khiri H, Tamalet C: Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases. Antivir Ther 2006, 11(8):1103-1106.
• [42]Pallier C, Rodriguez C, Brillet R, Nordmann P, Hezode C, Pawlotsky JM: Complex dynamics of hepatitis B virus resistance to adefovir. Hepatology 2009, 49(1):50-59.
• [43]Vigano M, Lampertico P, Iavarone M: High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B. J Hepatol 2009, 50:S338-339.